WallStreetZenWallStreetZen

NYSE: NVS
Novartis Ag Stock Forecast, Predictions & Price Target

Open Broker Account

Should I buy or sell NVS stock?

Based on 1 analyst offering ratings for Novartis Ag.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NVS stock forecasts and price targets.

NVS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Wolfe Research
Top 46%
55
HoldDowngradesN/AN/A2022-05-09
Exane BNP Paribas
HoldDowngradesN/AN/A2021-12-06
Bryan Garnier
HoldDowngradesN/AN/A2021-12-03

1 of 1

Forecast return on equity

Is NVS forecast to generate an efficient return?
Company
26.3%
Industry
91.67%
Market
121.74%
NVS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NVS forecast to generate an efficient return on assets?
Company
13.47%
Industry
17.84%
NVS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NVS earnings per share forecast

What is NVS's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$6.06-41.11%
Avg 2 year Forecast
$6.71-34.79%
Avg 3 year Forecast
$7.11-30.9%
NVS's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

NVS revenue forecast

What is NVS's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$52.0B-1.53%
Avg 2 year Forecast
$53.6B+1.6%
Avg 3 year Forecast
$54.3B+2.82%
NVS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NVS earnings growth forecast

How is NVS forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
-11.3%
Industry
13.64%
Market
16.88%
NVS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
NVS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
NVS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

NVS revenue growth forecast

How is NVS forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
1.04%
Industry
0.94%
Market
8.59%
NVS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NVS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NVS vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
NVS$76.01N/AN/AHold
AZN$54.84$75.00+36.76%Buy
BMY$71.09$75.90+6.77%Buy
AMGN$225.40$239.50+6.26%Hold
MRK$86.12$99.39+15.40%Buy

Novartis Ag Stock Forecast FAQ

Is Novartis Ag Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSE: NVS) stock is to Hold NVS stock.

Out of 1 analyst, 0 (0%) are recommending NVS as a Strong Buy, 0 (0%) are recommending NVS as a Buy, 1 (100%) are recommending NVS as a Hold, 0 (0%) are recommending NVS as a Sell, and 0 (0%) are recommending NVS as a Strong Sell.

If you're new to stock investing, here's how to buy Novartis Ag stock.

What is NVS's Earnings Per Share (EPS) forecast for 2022-2024?

(NYSE: NVS) Novartis Ag's current Earnings Per Share (EPS) is $10.29. On average, analysts forecast that NVS's EPS will be $6.06 for 2022, with the lowest EPS forecast at $6.00, and the highest EPS forecast at $6.22. On average, analysts forecast that NVS's EPS will be $6.71 for 2023, with the lowest EPS forecast at $6.60, and the highest EPS forecast at $6.84. In 2024, NVS's EPS is forecast to hit $7.11 (min: $7.03, max: $7.18).

What is NVS's forecast return on equity (ROE) for 2022-2025?

(NYSE: NVS) forecast ROE is 26.3%, which is considered strong.

What is NVS's earnings growth forecast for 2022-2024?

(NYSE: NVS) Novartis Ag's forecast annual earnings growth rate of -11.3% is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 13.64%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.88%.

Novartis Ag's earnings in 2022 is $22,982,000,000.On average, 4 Wall Street analysts forecast NVS's earnings for 2022 to be $13,319,880,000, with the lowest NVS earnings forecast at $13,188,000,000, and the highest NVS earnings forecast at $13,671,560,000. On average, 4 Wall Street analysts forecast NVS's earnings for 2023 to be $14,748,580,000, with the lowest NVS earnings forecast at $14,506,800,000, and the highest NVS earnings forecast at $15,034,320,000.

In 2024, NVS is forecast to generate $15,627,780,000 in earnings, with the lowest earnings forecast at $15,451,940,000 and the highest earnings forecast at $15,781,640,000.

What is NVS's revenue growth forecast for 2022-2024?

(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of 1.04% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 0.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.59%.

Novartis Ag's revenue in 2022 is $52,788,000,000.On average, 2 Wall Street analysts forecast NVS's revenue for 2022 to be $114,250,193,680,000, with the lowest NVS revenue forecast at $112,999,883,360,000, and the highest NVS revenue forecast at $115,500,504,000,000. On average, 2 Wall Street analysts forecast NVS's revenue for 2023 to be $117,886,026,370,000, with the lowest NVS revenue forecast at $115,888,736,740,000, and the highest NVS revenue forecast at $119,883,316,000,000.

In 2024, NVS is forecast to generate $119,300,780,060,000 in revenue, with the lowest revenue forecast at $116,065,258,120,000 and the highest revenue forecast at $122,536,302,000,000.

What is NVS's forecast return on assets (ROA) for 2022-2025?

(NYSE: NVS) forecast ROA is 13.47%, which is lower than the forecast US Drug Manufacturers - General industry average of 17.84%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.